News

Accovion provides study planning and management, clinical monitoring, pharmacovigilance including post-marketing safety, data management, biostatistics, statistical programming, medical writing and electronic publishing. Accovion chief operating officer Ivana Waller

Under the terms of the agreement, GSK will acquire Maxinutrition’s brands, including Maximuscle. GSK said the deal will extend its reach into wider categories, complementing its existing Nutritional

Teva‘s requests in this CP are based on the inability to establish acceptable ‘sameness’ of the active ingredients in glatiramer acetate, the complexity of the mechanism of action

Serodus has in-licensed RO1160367, a drug candidate ready to enter a clinical Phase II Proof-of-Concept study in heart failure. Under the Agreement, Serodus will receive the full preclinical

The data showed that the two antibodies plus docetaxel, given in the neoadjuvant setting prior to surgery, improved the rate of complete tumor disappearance in the breast by

Thelin will be withdrawn in regions where it is approved – the European Union, Canada and Australia, and the clinical studies of the drug will also be discontinued

The revised dosing recommendation extends the same dosing already approved for treatment-naive patients – Prezista, co-administered with ritonavir in combination with other antiretroviral agents and with food, once-daily

Actis will sell its 63% holding in Paras Pharma to RB. Reportedly, Sequoia Capital and the remaining shareholders, including Paras founder Girish Patel and his family, will also

Roxro Pharma obtained FDA approval for Sprix (ketorolac tromethamine) nasal spray in May of 2010, for the short-term (up to 5 days) management of acute moderate to moderately